RNAi Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

The RNAi therapeutics market is expected to grow at a significant CAGR of 17.4% during the forecast period (2023-2030), driven by factors like rising chronic diseases and increasing R&D investments.

Key players are Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Silence Therapeutics, Arrowhead Pharmaceuticals, Inc, Sanofi, GlaxoSmithKline Plc, Arbutus Biopharma Corporation, Benitec Biopharma, Thermo Fisher Scientific Inc and Sirnaomics, Inc.

Answer: Despite its potential, the market faces challenges like stringent regulatory requirements, complex delivery mechanisms, and high development costs. However, advancements in nanotechnology and increasing collaborations offer promising solutions.

RNAi therapeutics hold potential in treating various diseases, with the oncology segment currently holding the largest market share. Other promising applications include treatments for neurodegenerative diseases, infectious diseases, and rare genetic disorders.